Paediatric Intensive Care Unit

Midazolam pathway for management of Continuous Epileptiform Seizures

Staff relevant to:	Children's Hospital PICU/CICU/HDU medical/nursing staff under supervision of PICU Consultant
Approval date:	April 2022
Version:	3
Revision due:	April 2025
Written by:	Claire Westrope
Trust Ref:	C114/2016

1. Introduction and Who Guideline applies to

The following pathway is for the use of an escalating midazolam infusion for the control of continuous epileptiform seizure activity resistant to other medication or status epileticus pathway, in PICU/CICU

Scope

This pathway should only be used by Children's Hospital PICU/CICU/HDU medical/nursing staff under supervision of PICU Consultant, where possible with input from Paediatric Neurologist

Related documents:

For guidance within UHL Children's Emergency department please see:

Status Epilepticus in Children UHL Paediatric Emergency Department Guideline Trust ref: C33/2016

For guidance within UHL Children's Hospital please see:

Status Epilepticus UHL Childrens Hospital Guideline Trust ref: D1/2022

2. Midazolam seizure control pathway



Title: Midazolam pathway for management of continuous epileptiform seizures
V:3 Approved by: PICU Clinical Practice Group: April 2022 Next Review: April 2025
Trust Ref No: C114/2016



Title: Midazolam pathway for management of continuous epileptiform seizures
V:3 Approved by: PICU Clinical Practice Group: April 2022 Next Review: April 2025
Trust Ref No: C114/2016

3. Education and Training

None

4. Supporting References

None

5. Key Words

Continuous epileptiform seizure, Midazolam, PICU/CICU, Status epileticus, Thiopentone

---

The Trust recognises the diversity of the local community it serves. Our aim therefore is to provide a safe environment free from discrimination and treat all individuals fairly with dignity and appropriately according to their needs.
As part of its development, this policy and its impact on equality have been reviewed and no detriment was identified.

CONTACT AND REVIEW DETAILS	
Guideline Lead (Name and Title) Claire Westrope - Consultant	**Executive Lead** Chief Nurse
Details of Changes made during review: Updated midazolam seizure control pathway to include: • follow APLS seizure algorithm • consider sevoflurane via AnaConDa device and propofol infusion in cases of EEG seizures	